

**DRAFT
TOXICOLOGICAL PROFILE FOR
SELENIUM**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.


The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, N.E.
Mail Stop E-29
Atlanta, Georgia 30333

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on October 21, 1999 (64 FR 56792). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); and November 17, 1997 (62 FR 61332). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, reading "Jeffrey P. Koplan". The signature is fluid and cursive, with the first name "Jeffrey" being more prominent and the last name "Koplan" following in a similar style.

Jeffrey P. Koplan, M.D., M.P.H.

Administrator

Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 **Fax:** (404) 498-0057
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

John Risher, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

A. Rosa McDonald, Ph.D.
Mario J. Citra, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for selenium. The panel consisted of the following members:

1. Maryce M. Jacobs, Ph.D., Private Consultant, McLean, Virginia
2. Donald Lisk, Ph.D., Cornell University, Ithaca, New York
3. Craig Schnell, Ph.D., Private Consultant, Fargo, North Dakota
4. Calvin Willnite, Ph.D., Staff Toxicologist, Fremont, California

These experts collectively have knowledge of selenium's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS SELENIUM?	1
1.2 WHAT HAPPENS TO SELENIUM WHEN IT ENTERS THE ENVIRONMENT?	3
1.3 HOW MIGHT I BE EXPOSED TO SELENIUM?	4
1.4 HOW CAN SELENIUM ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN SELENIUM AFFECT MY HEALTH?	6
1.6 HOW CAN SELENIUM AFFECT CHILDREN?	8
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO SELENIUM?	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO SELENIUM?	9
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	10
1.10 WHERE CAN I GET MORE INFORMATION?	11
2. RELEVANCE TO PUBLIC HEALTH	13
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO SELENIUM IN THE UNITED STATES	13
2.2 SUMMARY OF HEALTH EFFECTS	15
2.3 MINIMAL RISK LEVELS	20
3. HEALTH EFFECTS	23
3.1 INTRODUCTION	23
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	24
3.2.1 Inhalation Exposure	26
3.2.1.1 Death	26
3.2.1.2 Systemic Effects	30
3.2.1.3 Immunological and Lymphoreticular Effects	35
3.2.1.4 Neurological Effects	35
3.2.1.5 Reproductive Effects	36
3.2.1.6 Developmental Effects	36
3.2.1.7 Cancer	36
3.2.2 Oral Exposure	36
3.2.2.1 Death	76
3.2.2.2 Systemic Effects	79
3.2.2.3 Immunological and Lymphoreticular Effects	97

3.2.2.4	Neurological Effects	100
3.2.2.5	Reproductive Effects	104
3.2.2.6	Developmental Effects	107
3.2.2.7	Cancer	110
3.2.3	Dermal Exposure	117
3.2.3.1	Death	117
3.2.3.2	Systemic Effects	117
3.2.3.3	Immunological and Lymphoreticular Effects	118
3.2.3.4	Neurological Effects	119
3.2.3.5	Reproductive Effects	119
3.2.3.6	Developmental Effects	119
3.2.3.7	Cancer	119
3.2.4	Other Routes of Exposure	120
3.3	GENOTOXICITY	120
3.4	TOXICOKINETICS	128
3.4.1	Absorption	136
3.4.1.1	Inhalation Exposure	136
3.4.1.2	Oral Exposure	137
3.4.1.3	Dermal Exposure	139
3.4.1.4	Other Routes of Exposure	140
3.4.2	Distribution	140
3.4.2.1	Inhalation Exposure	140
3.4.2.2	Oral Exposure	140
3.4.2.3	Dermal Exposure	143
3.4.2.4	Other Routes of Exposure	143
3.4.3	Metabolism	144
3.4.4	Elimination and Excretion	151
3.4.4.1	Inhalation Exposure	151
3.4.4.2	Oral Exposure	151
3.4.4.3	Dermal Exposure	153
3.4.4.4	Other Routes of Exposure	153
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	154
3.5	MECHANISMS OF ACTION	162
3.5.1	Pharmacokinetic Mechanisms	162
3.5.2	Mechanisms of Toxicity	163
3.5.3	Animal-to-Human Extrapolations	164
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	164
3.7	CHILDREN'S SUSCEPTIBILITY	168
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	170
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Selenium	172
3.8.2	Biomarkers Used to Characterize Effects Caused by Selenium	175
3.9	INTERACTIONS WITH OTHER CHEMICALS	176
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	180
3.11	METHODS FOR REDUCING TOXIC EFFECTS	181
3.11.1	Reducing Peak Absorption Following Exposure	181
3.11.2	Reducing Body Burden	182
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	182
3.12	ADEQUACY OF THE DATABASE	183
3.12.1	Existing Information on Health Effects of Selenium	183
3.12.2	Identification of Data Needs	187

3.12.3	Ongoing Studies	195
4.	CHEMICAL AND PHYSICAL INFORMATION	201
4.1	CHEMICAL IDENTITY	201
4.2	PHYSICAL AND CHEMICAL PROPERTIES	201
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	213
5.1	PRODUCTION	213
5.2	IMPORT/EXPORT	214
5.3	USE	214
5.4	DISPOSAL	219
6.	POTENTIAL FOR HUMAN EXPOSURE	221
6.1	OVERVIEW	221
6.2	RELEASES TO THE ENVIRONMENT	223
6.2.1	Air	223
6.2.2	Water	228
6.2.3	Soil	229
6.3	ENVIRONMENTAL FATE	229
6.3.1	Transport and Partitioning	229
6.3.2	Transformation and Degradation	232
6.3.2.1	Air	232
6.3.2.2	Water	233
6.3.2.3	Sediment and Soil	234
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	235
6.4.1	Air	235
6.4.2	Water	236
6.4.3	Sediment and Soil	237
6.4.4	Other Environmental Media	238
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	241
6.6	EXPOSURES OF CHILDREN	259
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	260
6.8	ADEQUACY OF THE DATABASE	261
6.8.1	Identification of Data Needs	261
6.8.2	Ongoing Studies	265
7.	ANALYTICAL METHODS	267
7.1	BIOLOGICAL MATERIALS	267
7.2	ENVIRONMENTAL SAMPLES	276
7.3	ADEQUACY OF THE DATABASE	278
7.3.1	Identification of Data Needs	278
7.3.2	Ongoing Studies	280
8.	REGULATIONS AND ADVISORIES	281
9.	REFERENCES	293
10.	GLOSSARY	381

APPENDICES

A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D.	INDEX	D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Selenium - Inhalation	29
3-2. Levels of Significant Exposure to Selenium - Oral	62
3-3. Levels of Significant Exposure to Selenium Sulfides - Oral	73
3-4. Metabolic Pathways for Selenium	145
3-5. Proposed Pathway for Formation of Dimethyl Selenide from Selenite in Animals	149
3-6. Activation and Reduction of Selenate to Selenite in Yeast <i>Saccharomyces cerevisiae</i>	150
3-7. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	157
3-8. Selenite Model, a Kinetic Model for Selenite Metabolism	158
3-9. Selenomethionine Model, a Kinetic Model for Selenomethionine Metabolism	161
3-10. Existing Information on Health Effects of Selenium	185
6-1. Frequency of NPL Sites with Selenium Contamination	222

LIST OF TABLES

3-1. Levels of Significant Exposure to Selenium - Inhalation	27
3-2. Levels of Significant Exposure to Selenium - Oral	37
3-3. Levels of Significant Exposure to Selenium Sulfides - Oral	69
3-4. Genotoxicity of Selenium <i>In Vitro</i>	122
3-5. Genotoxicity of Selenium <i>In Vivo</i>	124
3-6. Selenium Concentrations in Human Tissues	129
3-7. Biomarkers: Selenium Concentrations in Human Tissues and Fluids	133
3-8. On-going Studies on Selenium Health Effects	196
4-1. Chemical Identity of Selenium and Selected Compounds	202
4-2. Physical and Chemical Properties of Selenium and Selenium Compounds	206
5-1. Facilities that Produce, Process, or Use Selenium	215
5-2. Facilities that Produce, Process, or Use Selenium Compounds	216
5-3. Some Selenium Compounds and Their Uses	218
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Selenium	224
6-2. Releases to the Environment from Facilities that Produce, Process, or Use Selenium Compounds	225
6-3. Selenium Concentrations in Foods in the United States	240
6-4. U.S. Food and Drug Administration—Total Diet Study (TDS)—Market Baskets 91-3 through 99-1	242
6-5. Ongoing Studies on Selenium	266
7-1. Analytical Methods for Determining Selenium in Biological Materials	268
7-2. Analytical Methods for Determining Selenium in Environmental Samples	270
8-1. Regulations and Guidelines Applicable to Selenium	282